Skip to content
10-K

Annual Report

SAB Biotherapeutics, Inc. SABS SABSW

0000950170-25-046994

← back to feed
Filed
Mar 31, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2024 · Mar 21, 2025 9.29M sh
Shares Diluted FY 2024 · Dec 31, 2023 5.52M sh
Capex FY 2024 · Dec 31, 2023 $197.15K
Operating Cash Flow FY 2024 · Dec 31, 2023 −$25.12M
Short Term Investments FY 2024 · Dec 31, 2023 $0
Cash And Equivalents FY 2024 · Dec 31, 2023 $56.57M
Current Liabilities FY 2024 · Dec 31, 2023 $10.81M
Total Liabilities FY 2024 · Dec 31, 2023 $26.64M
Current Assets FY 2024 · Dec 31, 2023 $58.91M
Total Assets FY 2024 · Dec 31, 2023 $83.94M
Eps Diluted FY 2024 · Dec 31, 2023 −$7.64
Eps Basic FY 2024 · Dec 31, 2023 −$7.64
Sga Expense FY 2024 · Dec 31, 2023 $23.8M
Rd Expense FY 2024 · Dec 31, 2023 $16.52M
Net Income FY 2024 · Dec 31, 2023 −$42.19M
Operating Income FY 2024 · Dec 31, 2023 −$38.08M
Revenue FY 2024 · Dec 31, 2023 $2.24M
Stockholders Equity FY 2024 · Dec 31, 2022 $31.06M